Kiniksa Pharmaceuticals, Ltd. - (KNSA): Price and Financial Metrics
GET POWR RATINGS... FREE!
KNSA Stock Price Chart Interactive Chart >
KNSA Price/Volume Stats
| Current price | $14.76 | 52-week high | $28.67 |
| Prev. close | $14.61 | 52-week low | $13.00 |
| Day low | $14.39 | Volume | 322,200 |
| Day high | $14.81 | Avg. volume | 465,845 |
| 50-day MA | $15.13 | Dividend yield | N/A |
| 200-day MA | $17.69 | Market Cap | 1.01B |
Kiniksa Pharmaceuticals, Ltd. - (KNSA) Company Bio
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda
Latest KNSA News From Around the Web
Below are the latest news stories about Kiniksa Pharmaceuticals Ltd that investors may wish to consider to help them evaluate KNSA as an investment opportunity.
Kiniksa outlines development path for mavrilimumab after FDA feedbackPhoto by Sarah Silbiger/Getty Images News via Getty Images After receiving the feedback from the FDA, Kiniksa Pharmaceuticals (KNSA) summarized the path for registration for its experimental human monoclonal antibody, mavrilimumab in COVID-19-related ARDS, giant cell arteritis ((GCA)), and rheumatoid arthritis ((RA)). Based on results from the Phase 2 portion of the... |
Kiniksa Announces Issuance of U.S. Patent for Treatment of Recurrent PericarditisHAMILTON, Bermuda, June 08, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today announced that the U.S Patent and Trademark Office issued a patent covering methods of using ARCALYST® (rilonacept) in the treatment of recurrent pericarditis. The patent issued as U.S. Patent No. 11,026,997 and will expire on March 11, 2039. Kiniksa ha |
Kiniksa Outlines Next Steps for the Development of Mavrilimumab- Defined regulatory pathway for Phase 3 clinical development of mavrilimumab in multiple indications - - Continued development in COVID-19-related ARDS represents fastest path to potential registration for mavrilimumab; Phase 3 data expected in Q1 2022 - HAMILTON, Bermuda, June 08, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, tod |
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOsHere's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB ) Nuvation Bio Inc. (NYSE: NUVB ) PDS Biotechnology Corporation (NASDAQ: PDSB ) Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS ) PLx Pharma Inc. (NASDAQ: PLXP ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 26) Assembly Biosciences, Inc. (NASDAQ: ASMB ) Axcella Health Inc. (NASDAQ: AXLA ) Black Diamond Therapeutics, Inc. (NASDAQ: BDTX ) Bolt Biotherapeutics, Inc. (NASDAQ: BOLT ) Coherus BioSciences, Inc. (NASDAQ: CHRS ) Evofem Biosciences, Inc. (NASDAQ: EVFM ) Impel NeuroPharma, Inc. (NASDAQ: IMPL ) IMV Inc. (NASDAQ: IMV ) Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT... |
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics DebutsHere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Novo Nordisk A/S (NYSE: NVO ) Vaccitech plc (NASDAQ: VACC ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 13) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) ADC Therapeutics SA (NYSE: ADCT ) Accelerate Diagnostics, Inc. (NASDAQ: AXDX ) Achilles Therapeutics plc (NASDAQ: ACHL ) Akouos, Inc. (NASDAQ: AKUS ) (announced its first-quarter results) Applied Genetic Technologies Corporation (NASDAQ: AGTC ) Aprea Therapeutics, Inc. (NASDAQ: APRE ) Aquestive Therapeutics, Inc. (NASDAQ: AQST ) Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) Atreca, ... |
KNSA Price Returns
| 1-mo | 4.68% |
| 3-mo | -26.71% |
| 6-mo | -23.92% |
| 1-year | -39.03% |
| 3-year | -15.66% |
| 5-year | N/A |
| YTD | -16.47% |
| 2020 | 59.76% |
| 2019 | -60.63% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...